Hengrui Pharma (01276) has issued an announcement revealing that, as of August 31, 2026, the company has not yet started implementing its share repurchase plan.
According to the disclosure, as of the date of this announcement, there is no discrepancy between the actual progress of the buyback and the terms outlined in the repurchase scheme.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.